Headline
The latest stories from AHA Today.
The rise in COVID-19 cases due to the delta variant “continues to exacerbate the shortage of hospital workers, hampering recruitment and retention, driving up wages and weighing on hospitals' profitability,” according to a report released by Moody’s Investors Service.
As recommended by the AHA, the Food and Drug Administration proposed revising 2016 draft guidance to allow hospital and health system pharmacies that are not outsourcing facilities to distribute compounded drug products to any health care facility in the same system without first receiving a valid…
The AHA urged congressional leaders to include in year-end legislation provisions to extend the moratorium on Medicare sequester cuts and to prevent the Statutory Pay-As-You-Go Act of 2010 (Statutory PAYGO) sequester from taking effect at the end of this session of Congress.
Within the Grand Rapids, Mich., community, the COVID-19 pandemic exacerbated already worrisome increases in behavioral health needs and suicide ideation among children.
About 275,000 low-income adults are now eligible for coverage under Medicaid expansion in Missouri, the Centers for Medicare & Medicaid Services announced.
The U.S. Chamber of Commerce and 21 other organizations, including the AHA, urged Congress to maintain the current legal and regulatory framework for evaluating mergers and acquisitions.
Anthem, the country’s second-biggest health insurance company, is behind on billions of dollars in payments owed to hospitals and doctors because of onerous new reimbursement rules, computer problems and mishandled claims, says a Kaiser Health News article that is spotlighted in USA Today.
Kentucky, Maine and New Mexico have completed their transition from the federally facilitated marketplace to their own state-based marketplaces for the 2022 plan year, the Department of Health and Human Services announced.
Johnson & Johnson announced its request that the Food and Drug Administration amend the current emergency use authorization for the J&J COVID-19 vaccine to include a booster dose.
AstraZeneca said it has requested an emergency use authorization from the Food and Drug Administration for its long-acting antibody combination for the prevention of symptomatic COVID-19.